Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 5, 2003, Pages 459-464

  Nakamura, Yoichi ^a,c   Kunitoh, Hideo ^a   Kubota, Kaoru ^b   Sekine, Ikuo ^a   Yamamoto, Noboru ^a   Tamura, Tomohide ^a   Kodama, Tetsuro ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Recurrent disease

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; NEDAPLATIN; PACLITAXEL; VINDESINE;

ADENOCARCINOMA; ADULT; AGED; ALLERGY; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY REACTION; LETHARGY; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0141995650     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000037736.69148.F9     Document Type: Article

References (22)

1. Rapp E, Pater JL, William A, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer-report of a Canadian multicenter randomised trial. J Clin Oncol 1988;6:633-41.
2. Soquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
4. American Society of Clinical Oncology Group. Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997;15:2996-3018.
5. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997;24:455-62.
6. Belani CP. Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 1998;25(suppl 8):10-4.
7. Ferrigno D, Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 2000;29:91-104.
8. Fossella FV, Lee SJ, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995;13:645-51.
9. Burris H, Eckhardt J, Fields S, et al. Phase II trial of Taxotere in patients with non-small cell lung cancer [Abstract 1116]. Proc Am Soc Clin Oncol 1993;12:35.
10. Gandara DR, Vokes E, Green M, et al. Activity of docetaxel in platinum-treated non-small cell lung cancer. Results of a phase II multicenter trial. J Clin Oncol 2000;18:131-5.
11. Robinet G, Kleisbauer JP, Thomas P, et al. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC [Abstract 1726]. Proc Am Soc Clin Oncol 1997;16:480a.
12. Alexopoulos K, Kouroussis C, Androulakis N, et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trail. Cancer Chemother Pharmacol 1999;43:257-62.
13. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer. A Japanese cooperative study. J Clin Oncol 1996;14:1649-55.
14. Yamamoto N, Tamura T, Kamiya Y, et al. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol 2000;18:2301-8.
15. Japan Society for Cancer Therapy. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993;28:101-30.
16. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
17. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
20. Fossella FV, DeVore R, Kerr J, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimen. J Clin Oncol 2000;18:2354-62.
21. Yokoyama A, Kurita Y, Watanabe K, et al. Early phase II clinical study of RP 56976 (docetaxel) in patients with primary pulmonary cancer [in Japanese]. Jpn J Cancer Chemother 1994;21:2609-16.
22. Kudo S, Hino M, Fujita A, et al. Late phase II clinical study of RP 56976 in patients with non-small cell lung cancer [in Japanese]. Jpn J Cancer Chemother 1994;21:2617-23.